For decades, leukemia and lymphoma were treated with one approach: chemotherapy. It was brutal, unpredictable, and often left patients weaker than before. But today, a quiet revolution is underway. Targeted and cellular therapies are changing the game-offering more precision, fewer side effects, and in some cases, real cures where none existed before.
What Exactly Are Targeted Therapies?
Targeted therapies don’t attack all fast-growing cells like chemo does. They go after specific molecular weak spots in cancer cells. Think of it like using a key to unlock a single door instead of blowing up the whole building. For chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), two drugs have become standard: ibrutinib (Imbruvica) and venetoclax (Venclexta). Ibrutinib blocks a protein called Bruton’s tyrosine kinase (BTK), which leukemia cells need to survive. It’s taken as a pill, once a day. Venetoclax goes after BCL-2, a protein that keeps cancer cells from dying. Together, they can push the disease into deep remission. The big win? These drugs are oral, meaning patients don’t need hospital stays. A 2025 study from the CLL Society found that patients on targeted therapies took nearly twice as long to develop Richter transformation-a dangerous leap into aggressive lymphoma-compared to those on old-school chemo. The median time jumped from 2.2 years to 4.9 years. That’s not just a statistic. That’s extra years of working, traveling, watching your kids grow up.How CAR T-Cell Therapy Works
If targeted therapies are like precision missiles, CAR T-cell therapy is like training your own immune system to become a living weapon. Here’s how it works: First, doctors pull out your T cells-your body’s natural assassins-through a process called leukapheresis. Then, in a lab, those cells are genetically rewired to carry a special receptor called a chimeric antigen receptor (CAR). This CAR is designed to latch onto CD19, a protein found on most B-cell lymphomas and leukemias. The modified cells are multiplied, then infused back into you. The result? A living army of T cells that hunt down cancer like a GPS-guided missile. The first approved CAR T, tisagenlecleucel (Kymriah), was approved in 2017 for kids with relapsed acute lymphoblastic leukemia. Today, we have newer versions like axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (liso-cel). The numbers are staggering. In a 2025 trial for relapsed mantle cell lymphoma, a new CAR T called LV20.19 achieved a 100% response rate-with 88% of patients achieving complete remission. In another study, a dual-target CAR T that hits both CD19 and CD20 saw a 63.6% complete remission rate in patients who had failed every other treatment. For some, this is the first time they’ve been cancer-free in years.Targeted vs. Cellular: What’s the Difference?
It’s not a competition. They’re different tools for different jobs.| Feature | Targeted Therapies | Cellular Therapies (CAR T) |
|---|---|---|
| Administration | Oral pills, daily | Single IV infusion |
| Duration | Lifelong (unless stopped for resistance) | One-time treatment |
| Response Time | Weeks to months | Days to weeks |
| Major Toxicity | Bleeding, diarrhea, fatigue | Cytokine release syndrome, neurotoxicity |
| Cost (2025 avg) | $15,000-$25,000/month | $373,000-$475,000 total |
| Best For | Chronic, stable disease | Relapsed/refractory disease |
Targeted therapies are ideal for long-term control. Many patients stay on them for years. But resistance eventually builds. A 2025 review in the Journal of Clinical Oncology showed that BTK inhibitors typically work for 3-5 years before the cancer finds a way around them.
CAR T-cell therapy, on the other hand, is a one-shot deal. If it works, the immune cells stick around-sometimes for life. That’s why it’s reserved for patients who’ve tried everything else. But it’s also why it’s becoming a first-line option for high-risk cases. By 2030, 68% of hematologists predict CAR T will be used upfront for aggressive lymphomas.
Why This Isn’t Perfect Yet
These therapies are miracles-but they’re not magic. CAR T-cell therapy can trigger cytokine release syndrome (CRS), where the immune system goes haywire. Symptoms include high fever, low blood pressure, and trouble breathing. Neurotoxicity can follow, causing confusion, seizures, or even coma. About 20-40% of patients experience these side effects. That’s why it’s only given in certified centers with ICU access. Setting up a CAR T program takes 6-12 months and costs millions. Targeted drugs aren’t risk-free either. Venetoclax can cause tumor lysis syndrome-when dying cancer cells flood the bloodstream with toxins. That’s why patients start on low doses and are monitored in the hospital during the ramp-up. And then there’s cost. A single CAR T treatment can hit $400,000. Even with insurance, out-of-pocket costs can hit $15,000-$25,000 a month for targeted therapies. That’s why some doctors say we’re facing an ethical crisis: Who gets access when the price tag is so high?What’s Next? The Future Is Here
The next wave of therapies is already in the lab. Gilead’s Kite division is testing dual-target CAR T-cells like KITE-363 and KITE-753. These don’t just go after CD19-they also hit CD20. Why? Because cancer cells sometimes drop CD19 to escape treatment. With two targets, they can’t hide. Early data shows fewer relapses and less severe side effects. Some experts think this could make CAR T safe enough to give outside a hospital one day. New BTK inhibitors are also coming. Acalabrutinib (Calquence) is already in use, but next-gen versions aim to be more selective, cutting down on side effects like bleeding and atrial fibrillation. And then there’s the big question: Can we move CAR T earlier in treatment? Right now, it’s a last resort. But in 2025, the FDA gave priority review to liso-cel for marginal zone lymphoma-a sign that these therapies are expanding beyond the most desperate cases.
What Patients Need to Know
If you or someone you love has leukemia or lymphoma, here’s what matters:- Targeted therapies are great for long-term control, especially if you’re not a candidate for intensive treatment.
- CAR T-cell therapy is not a last-ditch effort anymore-it’s a real chance at cure, even after multiple relapses.
- Not every center can give CAR T. Ask if your hospital is certified by the FDA or NCI.
- Resistance to BTK inhibitors is common. If your cancer returns, don’t assume there’s nothing left. Clinical trials are expanding fast.
- Cost is a real barrier. Talk to your care team about financial aid programs. Many manufacturers offer patient support services.
There’s no one-size-fits-all anymore. A 72-year-old with CLL might do better on venetoclax and ibrutinib. A 35-year-old with relapsed lymphoma might have a shot at life-long remission with CAR T. The key is knowing your options-and having a team that knows how to use them.
Are targeted therapies better than chemotherapy for leukemia and lymphoma?
Yes, for most patients. Targeted therapies like ibrutinib and venetoclax are more effective, cause fewer side effects, and don’t require hospitalization. Studies show they extend progression-free survival and reduce complications like infections and organ damage that often follow chemo. They’re now the standard for CLL and many lymphomas, replacing older chemoimmunotherapy regimens.
Can CAR T-cell therapy cure lymphoma?
For some patients, yes. In relapsed or refractory large B-cell lymphoma, CAR T-cell therapy like Yescarta has shown 4-year survival rates of over 40%-a number unheard of just a decade ago. In mantle cell lymphoma, some patients achieve complete remission that lasts for years. While not every patient is cured, a significant portion live cancer-free without needing further treatment.
Why is CAR T-cell therapy so expensive?
It’s a personalized, one-time treatment made in a lab using your own cells. Each batch is custom-built, requiring specialized facilities, trained staff, and weeks of manufacturing. The process includes leukapheresis, genetic engineering, cell expansion, quality testing, and infusion-all under strict regulations. Plus, companies recover R&D costs from a small patient pool. The average cost is $373,000-$475,000, but financial assistance programs are widely available.
Do these therapies work for all types of leukemia and lymphoma?
No. Targeted therapies are most effective in B-cell cancers like CLL, SLL, follicular lymphoma, and mantle cell lymphoma. CAR T-cell therapy is approved for certain B-cell acute lymphoblastic leukemias and aggressive B-cell lymphomas. They don’t work for T-cell lymphomas or most AML cases-though trials are underway. Testing for specific markers like CD19, CD20, or BTK mutations is required before treatment.
What happens if targeted therapy stops working?
It’s common. Resistance often develops after 3-5 years. But that doesn’t mean there’s nothing left. Doctors can switch to another targeted drug, combine therapies, or move to CAR T-cell therapy. Trials are testing next-gen BTK inhibitors and drugs that target alternative pathways like PI3K or BCL-2. For patients with TP53 mutations, CAR T is often the best next step.
Is CAR T-cell therapy available everywhere?
No. Only about 89% of NCI-designated cancer centers offer it, and just 32% of community hospitals do. The reason? It requires specialized labs, ICU support, and staff trained in managing severe side effects like cytokine release syndrome. Patients often need to travel to a major center. Insurance usually covers it if you meet clinical criteria, but logistics can take weeks to arrange.
Final Thoughts
We’re no longer just trying to kill cancer. We’re learning to outsmart it. Targeted therapies give patients control. CAR T-cell therapy gives them hope. Together, they’ve turned once-fatal diseases into manageable ones-and in some cases, curable ones. The challenge now isn’t just science. It’s access. It’s cost. It’s making sure these breakthroughs don’t just help the lucky few, but everyone who needs them.For those facing leukemia or lymphoma today, the message is clear: There are more options than ever. And the future isn’t just about surviving-it’s about living.